Frankfurt
06.11.26 | 15:25
4,995 Euro
+0,60 % +0,030
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.10. | PolyPid unveils PD01B for diabetic foot infection treatment | 2 | Investing.com | ||
| 28.10. | PolyPid Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| POLYPID Aktie jetzt für 0€ handeln | |||||
| 27.10. | PolyPid spikes as Oppenheimer initiates at Outperform on lead asset | 2 | Seeking Alpha | ||
| 27.10. | Oppenheimer nimmt Beobachtung von PolyPid mit "Outperform" auf | 3 | Investing.com Deutsch | ||
| 27.10. | Oppenheimer initiates PolyPid stock coverage with outperform rating | 1 | Investing.com | ||
| 15.10. | PolyPid Ltd.: PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026 | 1 | GlobeNewswire (USA) | ||
| 01.10. | PolyPid Ltd.: European Medicines Agency Validates PolyPid's Marketing Authorization Application for D-PLEX100 | 5 | GlobeNewswire (USA) | ||
| 01.10. | PolyPid Ltd.: PolyPid Regains European Commercialization Rights for D-PLEX100, Expanding Global Commercialization Opportunities | 289 | GlobeNewswire (Europe) | PETACH TIKVA, Israel, Oct. 01, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by... ► Artikel lesen | |
| 01.10. | PolyPid Ltd. - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| 12.08. | PolyPid Ltd. - S-8, Securities to be offered to employees in employee benefit plans | 9 | SEC Filings | ||
| 12.08. | PolyPid GAAP EPS of -$0.35 beats by $0.03 | 5 | Seeking Alpha | ||
| 12.08. | PolyPid Ltd.: PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results | 1.352 | GlobeNewswire (Europe) | FDA Accepted D-PLEX100 NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance Exclusive U.S. and Canada Commercialization... ► Artikel lesen | |
| 12.08. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 30.07. | PolyPid Ltd.: PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026 | 7 | GlobeNewswire (USA) | ||
| 29.07. | PolyPid rises as lead product granted FDA priority review | 2 | Seeking Alpha | ||
| 29.07. | PolyPid's NDA For D-PLEX100 Receives FDA Priority Review, Stock Up | 1 | RTTNews | ||
| 29.07. | PolyPid Ltd.: PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX100 | 901 | GlobeNewswire (Europe) | PDUFA target action date of November 28, 2026, approximately one quarter ahead of Company's previously communicated guidance FDA identified no Filing review issues Acceptance triggers $15 million... ► Artikel lesen | |
| 29.07. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 22.07. | H.C. Wainwright reiterates Buy on PolyPid stock, $13 target | 3 | Investing.com | ||
| 21.07. | PolyPid, Azurity Pharmaceuticals Agree to Exclusive Commercial Partnership in US and Canada | 6 | Contract Pharma |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,25 | -0,38 % | Ihre wichtigsten Termine: Teamviewer, AMD, Booking, Amgen, Pfizer, Biontech & Bayer mit spannenden Zahlen! | © Foto: Arnulf Hettrich - imageBROKER.comGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene... ► Artikel lesen | |
| EVOTEC | 3,164 | +2,33 % | Der BioTech-Ausbruch: Bayer und Eli Lilly zeigen Muskeln - sind Novo Nordisk, Evotec und BioNxt die nächsten Gewinner? | Das war eine Abverkaufswoche an der NASDAQ! Ganze 5 % verlor der Technologie-Index von seinem erneuten Versuch die 30.000 Punkte-Marke zu überschreiten. Die zuvor exzellent gelaufenen Chip-Titel gerieten... ► Artikel lesen | |
| AMGEN | 414,10 | +0,28 % | Amgen: $10.4 Billion Q3 Revenue Reflects 8% Growth As Repatha, UPLIZNA And IMDELLTRA Sales Accelerate | ||
| VALNEVA | 2,499 | +0,40 % | Valneva: Britische Zulassung für Ixchiq widerrufen - der Druck auf die Aktie bleibt hoch | ||
| PALATIN TECHNOLOGIES | 6,480 | +3,35 % | This Palatin Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday | ||
| OCUGEN | 0,841 | +1,33 % | Ocugen im Check: OCU400-Lizenz für MENA - der nächste Baustein | ||
| VIKING THERAPEUTICS | 24,050 | -0,41 % | Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors. | ||
| DEFENCE THERAPEUTICS | 0,206 | -5,94 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Convertible Debenture Interest Payment | Montreal, Quebec--(Newsfile Corp. - October 23, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 0,618 | +0,98 % | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update
Ongoing negotiations with different parties towards securing a partnership or financing for the development... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,300 | -7,69 % | 2 Seiten der Läsion, p 0,01 und p 0,04: Warum NurExone neben Bewegung auch Myelin misst | ||
| ABIVAX | 77,55 | +0,98 % | EQS-News: ABIVAX: Abivax to Participate in Upcoming Fall Investor Conferences | EQS-News: ABIVAX
/ Key word(s): Conference
Abivax to Participate in Upcoming Fall Investor Conferences
02.11.2026 / 22:05 CET/CEST
The issuer is solely responsible for... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,960 | -0,37 % | SRPT Q3 Earnings Miss Estimates, Stock Down as Elevidys Sales Decline | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,070 | +2,22 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - 10-Q, Quarterly Report | ||
| IBIO | 0,649 | -2,41 % | iBio, Inc.: iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update | SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 51,64 | -1,03 % | Arrowhead Pharmaceuticals: Optionen deuten auf Kursbewegung von 8,1 % nach Quartalszahlen hin |
Das Unternehmen POLYPID LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 4,995 Euro und damit +0,60 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYPID LTD finden Sie auf Wallstreet Online.